LivaNova Wins FDA Nod for aura6000 Sleep Apnea Device
Event summary
- LivaNova's aura6000 System received FDA premarket approval for treating moderate to severe obstructive sleep apnea (OSA) using proximal hypoglossal nerve stimulation (p-HGNS).
- The approval follows positive results from the OSPREY trial, showing 65% responder rate after 12 months of therapy.
- LivaNova is developing a next-generation device with MRI compatibility and rechargeable battery technology.
- The aura6000 System is the first HGNS device approved without CCC-related contraindications or pre-implantation DISE requirements.
The big picture
LivaNova's FDA approval for the aura6000 System positions it as a key player in the neurostimulation therapy space, offering an alternative to traditional OSA treatments. The company's focus on developing next-generation devices with advanced features like MRI compatibility and rechargeable batteries aligns with broader industry trends toward more sophisticated and patient-friendly medical technologies.
What we're watching
- Commercialization Pace
- How quickly LivaNova can bring the next-generation device to market after securing PMA supplement approval.
- Market Adoption
- Whether the aura6000 System can gain significant market share among OSA patients who are intolerant of PAP therapy.
- Technological Advancements
- The pace at which LivaNova integrates MRI compatibility and long-lasting battery technology into its devices.
Related topics